• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

胰腺导管腺癌肿瘤细胞中的免疫检查点全景。

The Immune Checkpoint Landscape in Tumor Cells of Pancreatic Ductal Adenocarcinoma.

机构信息

Department of Surgery, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, 12203 Berlin, Germany.

Department of Surgery, Park-Klinik Weißensee, 13086 Berlin, Germany.

出版信息

Int J Mol Sci. 2023 Jan 21;24(3):2160. doi: 10.3390/ijms24032160.

DOI:10.3390/ijms24032160
PMID:36768480
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9917344/
Abstract

Immune checkpoint therapy (ICT) has shown promising potential in the treatment of multiple solid tumors. However, the role of ICT in pancreatic ductal adenocarcinoma (PDAC) remains limited. Patterns of immune checkpoints (ICs) in PDAC represent the basis for establishing a potent ICT. The aim of this study is to create a profile of IC expression and its prognostic relevance in cancer cells of PDAC. Therefore, tumor cells from peripheral and central tissue microarray (TMA) spots from histologically confirmed PDAC of 68 patients after tumor resection were investigated in terms of expressions of TIM3, IDO, B7H4, LAG3, VISTA, and PD-L1 using immunohistochemistry. The presence of the respective ICs was compared to overall survival (OS). The presence of VISTA and PD-L1 significantly correlates with shorter OS (median OS: 22 months vs. 7 months and 22 months vs. 11 months, respectively, < 0.05). For the presence of TIM3, IDO, B7H4, and LAG3, no difference in OS was observed ( > 0.05). The analysis of OS of combined subgroups for VISTA and PD-L1 (VISTA and PD-L1 neg., VISTA pos. and PD-L1 neg., VISTA neg. and PD-L1 pos., and VISTA and PD-L1 pos.) yielded overall statistical significance difference ( = 0.02). These results suggest that the presence of VISTA and PD-L1 is of prognostic relevance and potentially qualifies them as targets for ICT.

摘要

免疫检查点疗法 (ICT) 在治疗多种实体肿瘤方面显示出了巨大的潜力。然而,ICT 在胰腺导管腺癌 (PDAC) 中的作用仍然有限。PDAC 中的免疫检查点 (IC) 模式为建立有效的 ICT 提供了基础。本研究旨在创建 PDAC 癌细胞中 IC 表达及其预后相关性的图谱。因此,使用免疫组织化学方法研究了 68 例经组织学证实的 PDAC 患者肿瘤切除后外周和中央组织微阵列 (TMA) 点的肿瘤细胞中 TIM3、IDO、B7H4、LAG3、VISTA 和 PD-L1 的表达情况,并将其与总生存期 (OS) 进行了比较。分别观察到 VISTA 和 PD-L1 的存在与较短的 OS 显著相关(中位 OS:22 个月与 7 个月和 22 个月与 11 个月,分别为 <0.05)。对于 TIM3、IDO、B7H4 和 LAG3 的存在,OS 没有差异(>0.05)。对 VISTA 和 PD-L1 的联合亚组的 OS 分析显示具有总体统计学意义差异(=0.02)。这些结果表明,VISTA 和 PD-L1 的存在具有预后相关性,并可能使其成为 ICT 的潜在靶点。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b567/9917344/e7e977eb6943/ijms-24-02160-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b567/9917344/a6d8face39f4/ijms-24-02160-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b567/9917344/5dfa46a8109f/ijms-24-02160-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b567/9917344/202196e691f7/ijms-24-02160-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b567/9917344/e7e977eb6943/ijms-24-02160-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b567/9917344/a6d8face39f4/ijms-24-02160-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b567/9917344/5dfa46a8109f/ijms-24-02160-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b567/9917344/202196e691f7/ijms-24-02160-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b567/9917344/e7e977eb6943/ijms-24-02160-g004.jpg

相似文献

1
The Immune Checkpoint Landscape in Tumor Cells of Pancreatic Ductal Adenocarcinoma.胰腺导管腺癌肿瘤细胞中的免疫检查点全景。
Int J Mol Sci. 2023 Jan 21;24(3):2160. doi: 10.3390/ijms24032160.
2
Prognostic value, localization and correlation of PD-1/PD-L1, CD8 and FOXP3 with the desmoplastic stroma in pancreatic ductal adenocarcinoma.PD-1/PD-L1、CD8和FOXP3在胰腺导管腺癌中与促纤维增生性间质的预后价值、定位及相关性
Oncotarget. 2016 Jul 5;7(27):40992-41004. doi: 10.18632/oncotarget.10038.
3
Overexpressed histone acetyltransferase 1 regulates cancer immunity by increasing programmed death-ligand 1 expression in pancreatic cancer.组蛋白乙酰转移酶 1 过表达通过增加胰腺癌中程序性死亡配体 1 的表达来调节癌症免疫。
J Exp Clin Cancer Res. 2019 Feb 1;38(1):47. doi: 10.1186/s13046-019-1044-z.
4
Analysis of PD-L1 promoter methylation combined with immunogenic context in pancreatic ductal adenocarcinoma.分析胰腺导管腺癌中 PD-L1 启动子甲基化与免疫原性背景的关系。
Cancer Immunol Immunother. 2024 Jun 4;73(8):149. doi: 10.1007/s00262-024-03745-y.
5
Expression of B7 family checkpoint proteins in cervical cancer.B7 家族检查点蛋白在宫颈癌中的表达。
Mod Pathol. 2022 Jun;35(6):786-793. doi: 10.1038/s41379-021-00979-4. Epub 2021 Nov 30.
6
PD-L1 expression in pancreatic ductal adenocarcinoma is a poor prognostic factor in patients with high CD8 tumor-infiltrating lymphocytes: highly sensitive detection using phosphor-integrated dot staining.在CD8肿瘤浸润淋巴细胞高的胰腺癌患者中,程序性死亡受体配体1(PD-L1)表达是一个不良预后因素:使用磷整合点染色进行高灵敏度检测。
Int J Clin Oncol. 2017 Aug;22(4):726-733. doi: 10.1007/s10147-017-1112-3. Epub 2017 Mar 18.
7
Intratumoral neutrophil extracellular traps are associated with unfavorable clinical outcomes and immunogenic context in pancreatic ductal adenocarcinoma.肿瘤内中性粒细胞细胞外陷阱与胰腺导管腺癌不良的临床结局和免疫原性环境相关。
Front Immunol. 2022 Oct 17;13:1027459. doi: 10.3389/fimmu.2022.1027459. eCollection 2022.
8
Expression of Immune Checkpoint Regulators IDO, VISTA, LAG3, and TIM3 in Resected Pancreatic Ductal Adenocarcinoma.免疫检查点调节因子IDO、VISTA、LAG3和TIM3在切除的胰腺导管腺癌中的表达
Cancers (Basel). 2021 May 29;13(11):2689. doi: 10.3390/cancers13112689.
9
The Importance of a Conjoint Analysis of Tumor-Associated Macrophages and Immune Checkpoints in Pancreatic Cancer.肿瘤相关巨噬细胞与免疫检查点在胰腺癌中的联合分析的重要性。
Pancreas. 2019 Aug;48(7):904-912. doi: 10.1097/MPA.0000000000001364.
10
PD-L1 in pancreatic ductal adenocarcinoma: a retrospective analysis of 373 Chinese patients using an in vitro diagnostic assay.胰腺导管腺癌中程序性死亡受体配体1(PD-L1)的表达:采用体外诊断检测法对373例中国患者的回顾性分析
Diagn Pathol. 2018 Jan 17;13(1):5. doi: 10.1186/s13000-017-0678-4.

引用本文的文献

1
TIMEPOINT, a phase 1 study combining MTL-CEBPA with pembrolizumab, supports the immunomodulatory effect of MTL-CEBPA in solid tumors.TIMEPOINT,一项将MTL-CEBPA与帕博利珠单抗联合使用的1期研究,支持MTL-CEBPA在实体瘤中的免疫调节作用。
Cell Rep Med. 2025 Apr 15;6(4):102041. doi: 10.1016/j.xcrm.2025.102041. Epub 2025 Mar 31.
2
B7H4 Role in Solid Cancers: A Review of the Literature.B7H4在实体癌中的作用:文献综述
Cancers (Basel). 2024 Jul 11;16(14):2519. doi: 10.3390/cancers16142519.
3
Prognostic Value of B7H4 Expression in Patients with Solid Cancers: A Systematic Review and Meta-Analysis.

本文引用的文献

1
Immune checkpoint proteins: Signaling mechanisms and molecular interactions in cancer immunotherapy.免疫检查点蛋白:癌症免疫治疗中的信号机制和分子相互作用。
Semin Cancer Biol. 2022 Nov;86(Pt 3):137-150. doi: 10.1016/j.semcancer.2022.03.014. Epub 2022 Mar 24.
2
PD-L1 and PD-L2 expression in pancreatic ductal adenocarcinoma and their correlation with immune infiltrates and DNA damage response molecules.胰腺导管腺癌中 PD-L1 和 PD-L2 的表达及其与免疫浸润和 DNA 损伤反应分子的相关性。
J Pathol Clin Res. 2022 May;8(3):257-267. doi: 10.1002/cjp2.259. Epub 2022 Jan 17.
3
Expression of Immune Checkpoint Regulators IDO, VISTA, LAG3, and TIM3 in Resected Pancreatic Ductal Adenocarcinoma.
B7H4 表达在实体瘤患者中的预后价值:系统评价和荟萃分析。
Int J Mol Sci. 2024 May 6;25(9):5045. doi: 10.3390/ijms25095045.
4
Targeted Therapy for Highly Desmoplastic and Immunosuppressive Tumor Microenvironment of Pancreatic Ductal Adenocarcinoma.针对胰腺导管腺癌高度促纤维增生和免疫抑制肿瘤微环境的靶向治疗
Cancers (Basel). 2024 Apr 11;16(8):1470. doi: 10.3390/cancers16081470.
5
Unraveling the potential of CD8, CD68, and VISTA as diagnostic and prognostic markers in patients with pancreatic ductal adenocarcinoma.解析CD8、CD68和VISTA作为胰腺导管腺癌患者诊断和预后标志物的潜力。
Front Immunol. 2024 Jan 30;15:1283364. doi: 10.3389/fimmu.2024.1283364. eCollection 2024.
6
Polarization of Cancer-Associated Macrophages Maneuver Neoplastic Attributes of Pancreatic Ductal Adenocarcinoma.癌症相关巨噬细胞的极化调控胰腺导管腺癌的肿瘤特性
Cancers (Basel). 2023 Jul 5;15(13):3507. doi: 10.3390/cancers15133507.
免疫检查点调节因子IDO、VISTA、LAG3和TIM3在切除的胰腺导管腺癌中的表达
Cancers (Basel). 2021 May 29;13(11):2689. doi: 10.3390/cancers13112689.
4
Understanding LAG-3 Signaling.理解 LAG-3 信号通路。
Int J Mol Sci. 2021 May 17;22(10):5282. doi: 10.3390/ijms22105282.
5
The Next Decade of Immune Checkpoint Therapy.免疫检查点治疗的下一个十年。
Cancer Discov. 2021 Apr;11(4):838-857. doi: 10.1158/2159-8290.CD-20-1680.
6
Pancreatic Ductal Adenocarcinoma: Epidemiology and Risk Factors.胰腺导管腺癌:流行病学与危险因素
Diagnostics (Basel). 2021 Mar 20;11(3):562. doi: 10.3390/diagnostics11030562.
7
LAG-3-Expressing Tumor-Infiltrating T Cells Are Associated with Reduced Disease-Free Survival in Pancreatic Cancer.表达LAG-3的肿瘤浸润性T细胞与胰腺癌无病生存期缩短相关。
Cancers (Basel). 2021 Mar 15;13(6):1297. doi: 10.3390/cancers13061297.
8
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.《全球癌症统计数据 2020:全球 185 个国家和地区 36 种癌症的发病率和死亡率估计》。
CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4.
9
Pancreatic cancer and immune checkpoint inhibitors-still a long way to go.胰腺癌与免疫检查点抑制剂——仍有很长的路要走。
Transl Gastroenterol Hepatol. 2021 Jan 5;6:6. doi: 10.21037/tgh.2020.04.03. eCollection 2021.
10
Genomic investigation of co-targeting tumor immune microenvironment and immune checkpoints in pan-cancer immunotherapy.泛癌免疫治疗中共同靶向肿瘤免疫微环境和免疫检查点的基因组研究。
NPJ Precis Oncol. 2020 Nov 13;4(1):29. doi: 10.1038/s41698-020-00136-1.